New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
10:40 EDTDLR, KERX, VMW, TSNHigh option volume stocks: DLR KERX VMW TSN
News For DLR;KERX;VMW;TSN From The Last 14 Days
Check below for free stories on DLR;KERX;VMW;TSN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 9, 2014
19:39 EDTVMWVMware initiated with a Buy at Maxim
Target $120.00.
19:38 EDTDLRDigital Realty resumed with a Hold at Stifel
Subscribe for More Information
18:49 EDTDLRDigital Realty announces $188M Turn-Key Flex joint venture
Digital Realty announced the formation of a $187.6M joint venture between an affiliate of Digital Realty and an affiliate of Griffin Capital Essential Asset REIT, or GCEAR.. Digital Realty contributed to the joint venture, which was formed on September 9, an approximately 132,280 square foot Turn-Key Flex data center in Ashburn, Virginia valued at approximately $185.5M, excluding $2.1M of closing costs, or $20,611 per kW. The property is expected to generate forward 12-month cash net operating income of approximately $13.1M, representing a 7.05% cap rate. The property is 100% leased, with a weighted average remaining lease term of approximately seven years. GCEAR will hold an 80% interest in the joint venture and Digital Realty will retain a 20% interest. Digital Realty will continue to manage the property, and will receive management fees and will also be entitled to participate in certain excess cash flow and capital proceeds for managing the property. The joint venture has arranged a $102.0M five-year bank loan at LIBOR plus 225 basis points, representing a loan-to-value ratio of approximately 55%. The transaction generated net proceeds to Digital Realty of approximately $168.4M, comprised of Digital Realty's share of the initial draw-down on the bank loan in addition to the GCEAR fund's equity contribution, less Digital Realty's share of closing costs. Proceeds from the transaction will initially be used to pay down debt, and will eventually be used to fund ongoing investment activity and other corporate purposes. Digital Realty's FY14 core FFO per share guidance remains unchanged at $4.85-$4.95.
12:02 EDTKERXOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX CIEN FNSR PAY BKS PVH NAV BYI FTR JOY
05:36 EDTVMWVMware, Capgemini announce strategic partnership
Subscribe for More Information
September 8, 2014
16:18 EDTKERXOn The Fly: Closing Wrap
Subscribe for More Information
10:42 EDTKERXOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX CONN CIEN INSM FNSR PAY PVH SWY
10:06 EDTKERXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:29 EDTKERXKeryx downgraded to Underperform from Market Perform at FBR Capital
Subscribe for More Information
09:18 EDTKERXKeryx price target raised to $32 from $30 at Roth Capital
Subscribe for More Information
09:12 EDTKERXOn The Fly: Pre-market Movers
Subscribe for More Information
07:38 EDTKERXKeryx label for ferric citrate incrementally negative, says JPMorgan
JPMorgan says the approved label for Keryx's ferric citrate is incrementally negative given the lack of clear articulation of ESA/IV iron sparing data. The firm keeps an Overweight rating on the stock with a $24 price target, saying Keryx's 2024 patents are strong.
06:26 EDTKERXKeryx downgraded to Underperform from Market Perform at FBR Capital
September 5, 2014
14:39 EDTKERXKeryx falls after FDA approves drug with warnings on label
Subscribe for More Information
13:56 EDTKERXKeryx bounces off low following halt, levels to watch
Subscribe for More Information
13:44 EDTKERXKeryx reopens, down 12.5% to $15.74 after FDA approval of Ferric Citrate
13:27 EDTKERXKeryx label for Ferric Citrate positive, says Maxim
Maxim views the label for Keryx' newly-approved Ferric Citrate as a positive that suggests the drug could become the category leader. The firm noted the FDA is deliberating on NCE Status for the drug, which it also views as appearing positive, since the agency has rejected others. Maxim maintains its Buy rating and $24 price target on the stock, which remains halted for trade, with trading set to resume at 1:40 pm ET.
13:20 EDTKERXKeryx to resume trading at 1:40 pm ET
Subscribe for More Information
11:19 EDTKERXKeryx receives FDA approval of Ferric Citrate
Subscribe for More Information
10:50 EDTKERXKeryx trading halted, pending news
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use